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The combination products market has grown 
dramatically over the last decade. Comprised 
of two or more components of a drug, biologic, 
or device combined as a single entity, or 
co-packaged as separate cross-labeled products, 
this category of unique medical therapies can 
offer solutions that some single compounds 
cannot. 
Currently being used, or developed, in 
a wide range of areas including cardiology, 
oncology, neurology, diabetes, dermatology, 
gastroenterology, respiratory, and infectious 
diseases, their growth is in part due to their 
potential to improve efficacy, reduce pill burdens, 
increase compliance, ease administration, target 
delivery, allow controlled release, and in some 
cases even provide a more cost-effective option. 
With this kind of potential it is therefore not 
surprising that we find ourselves increasingly 
using these products in the treatments we 
are offering our patients. And with this we 
are finding ourselves becoming increasingly 
interested in the data and debate surrounding 
their mechanism of actions, efficacy, safety, 
and cost-effectiveness, as well as looking more 
closely into the pipeline for new innovative 
combination technologies which could offer our 
patients significant benefits.
With all this in mind, and the future for 
combination products looking bright, we need 
a resource which is easily accessible and can 
provide us with the data and concise answers 
we are looking for whilst still keeping us up to 
date on new products and issues in this ever 
changing area - and all in the most efficient way 
possible.
Combination Products in Therapy is an 
international, fully open access, peer reviewed, 
rapid publication journal focused on research 
around the discovery, development, delivery, 
and use of therapeutic and diagnostic 
combination products. 
Designed with the 21st century in mind, 
and permitted by our increasingly electronic 
environment, open access ensures increased 
global visibility of every article published and 
helps to disseminate the important information 
we are after as quickly and easily as possible. 
To further encourage a wider readership each 
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article has alongside it a bulleted summary 
slide, which is freely accessible to the reader 
and accompanies the article online, giving a 
time-efficient overview of the paper. There 
is also the option to include supplementary 
material, such as: videos, to clearly illustrate the 
main points; slide sets, to condense data more 
efficiently into bullets and graphics; animations, 
which are ideal education tools; talking abstracts, 
for ease of communication; and interactive case 
studies, to turn simple case reports into a step-
by-step learning quiz. 
Combination Products in Therapy is therefore, 
I believe, a welcome addition in educating 
ourselves and our patients on the latest 
combination therapies available. 
